AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28588165
Drug: Eptifibatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (10 mg intra coronary single bolus dose)
Trial: 25921451
Drug: Dornase alfa
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dornase alfa 2.5 mg/d via eRapid nebulizer
Trial: 23406890
Drug: Talking Parents,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talking Parents, Healthy Teens program (8 weekly 1-hour sessions)
Trial: 19589146
Drug: lafutidine 10
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lafutidine 10 mg with mosapride 5 mg
Trial: 20084717
Drug: Fluoropyrimidine-based hepatic
RxNorm normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluoropyrimidine-based hepatic arterial infusion (HAI) chemotherapy
Trial: 14995946
Drug: 7.5% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% NaCl infusion (4 ml kg‐1 over 10 min)
Trial: 7997323
Drug: oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral acyclovir (400 mg 5 times daily, n = 51)
Trial: 7997323
Drug: oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral acyclovir (400 mg 5 times daily)
Trial: 29458932
Drug: Arsenicum album
RxNorm normalized name: Homeopathic Substance Oral Tablet [ARSENICUM ALBUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arsenicum album 30cH (6 doses, thrice daily for two days)
Trial: 12971703
Drug: D-amphetamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (10 mg every fourth day, totalling 100 mg in 36 days)
Trial: 10702432
Drug: Modified left
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified left double-lumen tube (L-DLT)
Trial: 28778219
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine (TDB) patches starting at 5 μg/h, titrated to a maximum of 40 μg/h over 6 weeks, continued for 11 weeks.
Trial: 26547914
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine (TDB) patches
Trial: 26684994
Drug: Immersive Visualization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive Visualization (IV) eyewear during oral debridement (Group A)
Trial: 26684994
Drug: Immersive Visualization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive Visualization (IV) eyewear during oral debridement (Group B)
Trial: 18334706
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with PELF (cisplatin 40 mg/m² on days 1 and 5, epirubicin 30 mg/m² on days 1 and 5, L-leucovorin 100 mg/m² on days 1-4, and 5-fluorouracil 300 mg/m² on days 1-4)
Trial: 17190893
Drug: Alendronate 5
RxNorm normalized name: ALENDRONATE 5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 5 mg/d
Trial: 10731626
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg iv)
Trial: 10731626
Drug: MDMA (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (1.5 mg/kg po)
Trial: 3085428
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg diazepam orally
Trial: 3085428
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam as a rectal solution
Trial: 23313811
Drug: epratuzumab 2400
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epratuzumab 2400 mg cumulative dose (600 mg weekly)
Trial: 23313811
Drug: epratuzumab 2400
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epratuzumab 2400 mg cumulative dose (1200 mg EOW)
Trial: 23313811
Drug: epratuzumab 2400
RxNorm normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epratuzumab 2400 mg cumulative dose (all patients)
Trial: 20024491
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo rFVIIa administration (45, 90, or 180 microg/kg)
Trial: 20024491
Drug: Ex vivo
RxNorm normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo rFVIIa spiking (0.6, 1.2, or 2.4 microg/ml)
Trial: 20024491
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo rFVIIa administration
Trial: 2045762
Drug: Felodipine ER,
RxNorm normalized name: Felodipine ER, 5 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER, 10 mg once daily for 2 weeks
Trial: 2045762
Drug: Hydrochlorothiazide (HCTZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ), 25 mg once daily for 2 weeks
Trial: 25986447
Drug: Allopurinol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (600 mg daily)
Trial: 24867069
Drug: Arginine, glutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplementation (twice per day for 16 weeks)
Trial: 24867069
Drug: Control drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drink (twice per day for 16 weeks)
Trial: 22942114
Drug: HIFU treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU treatment at 47 J/cm² (141 J/cm² total)
Trial: 22942114
Drug: HIFU treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU treatment at 59 J/cm² (177 J/cm² total)
Trial: 22942114
Drug: HIFU treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU treatment (all energy levels)
Trial: 19127427
Drug: CC with
RxNorm normalized name: BD Syringe 5cc with Needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC with two doses rFSH
Trial: 17202560
Drug: Methylphenidate (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (54 mg/day)
Trial: 15609471
Drug: High-dose interleukin
RxNorm normalized name: interleukin-11
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interleukin (IL)-2 (Proleukin)
Trial: 15609471
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy with IL-2 and interferon-alfa (biochemotherapy)
Trial: 12562068
Drug: Proprioceptive neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprioceptive neuromuscular facilitation (PNF) training, 30 minutes daily for 10 treatments
Trial: 12562068
Drug: Traditional training,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional training, 30 minutes daily for 10 treatments
Trial: 11475729
Drug: Capsule of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule of Prostatitis decoction
Trial: 8580795
Drug: 400 mg/m2/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/m2/day etoposide
Trial: 8580795
Drug: 600 mg/m2/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/m2/day etoposide
Trial: 8580795
Drug: 200 mg/m2/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/m2/day etoposide (control group)
Trial: 2526769
Drug: Nicotinamide 3
RxNorm normalized name: PSATHYROTES RAMOSISSIMA WHOLE 36 g in 100 g / N-(HYDROXYMETHYL)NICOTINAMIDE 36 g in 100 g PERCUTANEOUS TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide 3 g/day for 9 months
Trial: 359494
Drug: Cetiedil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetiedil (100 mg, t.i.d.)
Trial: 359494
Drug: Theophylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (200 mg, t.i.d.)
Trial: 359494
Drug: Orciprenaline (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orciprenaline (20 mg, t.i.d.)
Trial: 359494
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mg Lactose, t.i.d.)
Trial: 31905644
Drug: Inspiratory Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory Muscle Training (IMT) for eight weeks with a commercially available respiratory muscle trainer (Threshold IMT), 80 inhalations (twice per day, five days per week)
Trial: 23220080
Drug: Niacinamide-containing formulations
RxNorm normalized name: Niacinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Niacinamide-containing formulations applied twice daily for 28 days
Trial: 21613278
Drug: Subcutaneous cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous cervical plexus block
Trial: 9264494
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 to 480 mg/d
Trial: 9264494
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 to 40 mg/d
Trial: 3107444
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure ventilator for 3 to 6 hours daily for 3 consecutive days (Group B)
Trial: 8083453
Drug: Methotrexate (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (15 mg weekly)
Trial: 27320562
Drug: PCA fentanyl
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA fentanyl with IV parecoxib 40 mg
Trial: 22651702
Drug: Bisoprolol dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol dose <5 mg
Trial: 8843172
Drug: Gliclazide (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (240 mg orally)
Trial: 1632534
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (ketorolac 60 mg IV and bupivacaine 0.5% 30 mL)
Trial: 1632534
Drug: Bupivacaine (0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.5% 30 mL)
Trial: 30753540
Drug: POIBA intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: POIBA intervention (9-session classroom program, 6 weekly physical education sessions, out-of-school physical activity, family workshop)
Trial: 27048410
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy for 8 weeks
Trial: 27048410
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (budesonide nasal spray with cetirizine tablets for 8 weeks)
Trial: 20682573
Drug: 1% plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% plain subcutaneous lidocaine
Trial: 17717933
Drug: Qishen Yiqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishen Yiqi Drop Pill
Trial: 15640488
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (6 g green tea solids)
Trial: 15640488
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (6 g black tea solids)
Trial: 15640488
Drug: Control (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (360 mg caffeine)
Trial: 7560667
Drug: Hydrocortisone sodium
RxNorm normalized name: Hydrocortisone Sodium Phosphate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone sodium succinate (100 mg administered intravenously)
Trial: 7560667
Drug: Aspirin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (oral challenge)
Trial: 2393271
Drug: Cefazolin (mean,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (mean, 178.6 mg/h)
Trial: 2393271
Drug: Cefuroxime (mean,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (mean, 330.0 mg/h)
Trial: 7015262
Drug: One-day regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day regimen of cefadroxil (30 mg/kg/day in two divided doses)
Trial: 7015262
Drug: Ten-day regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten-day regimen of cefadroxil (30 mg/kg/day in two divided doses)
Trial: 7015262
Drug: Short-term therapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term therapy (one or four days of antibiotics)
Trial: 7015262
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (ten-day regimen)
Trial: 7015262
Drug: Short-term therapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term therapy (all children in both studies)
Trial: 7015262
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (all children in both studies)
Trial: 30625184
Drug: Therapy dog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy dog exposure (15 min)
Trial: 24908551
Drug: Ritonavir-boosted protease
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted protease inhibitor with emtricitabine and tenofovir (no-switch group)
Trial: 20977611
Drug: Immediate implants
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implants with immediate loading (group A)
Trial: 19441871
Drug: Emtricitabine/tenofovir DF
RxNorm normalized name: COBICISTAT/ELVITEGRAVIR/EMTRICITABINE/TENOFOVIR DF TAB,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine/tenofovir DF 200 mg/300 mg once daily plus lopinavir/ritonavir
Trial: 19441871
Drug: Emtricitabine/tenofovir DF
RxNorm normalized name: COBICISTAT/ELVITEGRAVIR/EMTRICITABINE/TENOFOVIR DF TAB,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine/tenofovir DF 200 mg/300 mg once daily
Trial: 19441871
Drug: Emtricitabine/tenofovir DF
RxNorm normalized name: COBICISTAT/ELVITEGRAVIR/EMTRICITABINE/TENOFOVIR DF TAB,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine/tenofovir DF in combination with various boosted PIs
Trial: 17497471
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg once weekly (n = 47)
Trial: 17497471
Drug: Risedronate 35
RxNorm normalized name: risedronate 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 35 mg once weekly (n = 44)
Trial: 17497471
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg per day (n = 36)
Trial: 11246837
Drug: Educational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational group (group E) with antihypertensive drug treatment and patient education
Trial: 11246837
Drug: Routine group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine group (group R) with antihypertensive drug treatment alone
Trial: 7843814
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g administered intravenously within 1 h before surgery and a second dose 3-4 days postoperatively.
Trial: 7843814
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antibiotic prophylaxis).
Trial: 7843814
Drug: Ceftriaxone treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone treatment.
Trial: 28628810
Drug: GH administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH administration (starting dose 2μg/kg/d)
Trial: 23648162
Drug: Low VT
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low VT ventilation group (VT set on 6-7 ml/kg, high pressure alarm threshold adjusted to 60 cm H2O)
Trial: 23648162
Drug: Conventional VT
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional VT group (VT set at 8-12 ml/kg, high pressure alarm threshold at 40 cm H2O)
Trial: 19107089
Drug: Back School
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back School program (4 weekly classes of 60 minutes)
Trial: 15005771
Drug: Peanut flour
RxNorm normalized name: Peanut flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut flour in mashed potatoes (2.7, 8.9, or 26.8 mg)
Trial: 15005771
Drug: Hazelnut flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hazelnut flour in oatmeal porridge (74, 247, or 742 mg)
Trial: 8642803
Drug: Rilmenidine (RIL)
DrugBank: Rilmenidine (DB11738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine (RIL) 1 mg o.d. or b.i.d.
Trial: 8642803
Drug: Captopril (CAP)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CAP) 25 or 50 mg b.i.d.
Trial: 2158355
Drug: Naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50 mg once daily for 3 consecutive weeks
Trial: 465434
Drug: B‐complex vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B‐complex vitamins (4 mg riboflavin and 10 mg pyridoxine) daily for 1 month
Trial: 465434
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of gentian violet
Trial: 465434
Drug: No vitamin
RxNorm normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No vitamin supplements
Trial: 17431740
Drug: Randomized treatment
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized treatment (specific intervention details not available)
Trial: 9736546
Drug: Sparfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (400 mg loading dose on day 1, then 200 mg once daily)
Trial: 8527688
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg twice daily)
Trial: 2620055
Drug: Dinoprostone pessary
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone pessary (3 mg)
Trial: 29637896
Drug: Mg supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg supplementation
Trial: 15009866
Drug: Flecainide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (2 mg/kg as a 30-minute IV infusion) before electrical cardioversion
Trial: 15009866
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mL IV infusion of 5% glucose) 30 minutes before electrical cardioversion
Trial: 11587988
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone 500 microg twice daily
Trial: 9861787
Drug: Model for
RxNorm normalized name: Model AA 2012 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model for identification and resolution of medication problems
Trial: 7988630
Drug: Dihydrotachysterol preparations
RxNorm normalized name: Dihydrotachysterol
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrotachysterol preparations (capsules and oral solution)
Trial: 7988630
Drug: A.T.10 oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A.T.10 oral solution
Trial: 29884231
Drug: Clonidine (75μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (75μg every 3rd hour up to a maximum of 4 doses, then 75μg twice daily until delirium free for 2 days, discharge or a maximum of 7 days)
Trial: 25865041
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis started 24 hours pre intervention and for 5 days after
Trial: 20961566
Drug: Daily nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily nutritional supplementation for 6 months followed by daily GH therapy for 12 months
Trial: 20961566
Drug: Observation for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation for 6 months followed by daily GH therapy for 12 months
Trial: 30031369
Drug: Modified Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Cognitive Processing Therapy (SMART-CPT)
Trial: 26707905
Drug: Low AMH
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low AMH (<1.00 ng/mL; n = 124)
Trial: 26707905
Drug: Normal AMH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal AMH (1.00-3.5 ng/mL; n = 595)
Trial: 26707905
Drug: High AMH
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High AMH (>3.5 ng/mL; n = 483)
Trial: 24372829
Drug: Metoclopramide nasal
RxNorm normalized name: metoclopramide Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide nasal spray 20 mg